ATS: Aggressive Melanoma Linked to Severe, Untreated Sleep Apnea

Share this content:
ATS: Aggressive Melanoma Linked to Severe, Untreated Sleep Apnea
ATS: Aggressive Melanoma Linked to Severe, Untreated Sleep Apnea

TUESDAY, May 17, 2016 (HealthDay News) -- Severe, untreated cases of obstructive sleep apnea (OSA) are associated with more aggressive melanomas, according to findings presented at the annual meeting of the American Thoracic Society, held from May 13 to 18 in San Francisco.

The study involved 412 patients, averaging 55 years of age, all of whom had confirmed cases of cutaneous malignant melanoma. All of the patients were also studied to gauge how well they slept.

The researchers found that OSA was more common and severe for patients diagnosed with the most aggressive cancers. This was true even when they factored out other risk factors for melanoma such as age, gender, weight, skin type, and sun exposure.

"This is the first large, prospective multicenter study that was specifically constructed to look at the relationship between sleep apnea and a specific cancer," study author Miguel Angel Martinez-Garcia, M.D., Ph.D., from La Fe University and Polytechnic Hospital in Valencia, Spain, explained in an American Thoracic Society news release. "While more research is needed, this study shows that patients in the study had markers of poor prognosis for their melanoma. It also highlights the importance of diagnosing and treating sleep apnea."

Press Release
More Information

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions

More in Home

FDA Approves Kinase Inhibitor for Treatment of AML

FDA Approves Kinase Inhibitor for Treatment of AML

Midostaurin, in combination with chemotherapy, treats acute myeloid leukemia in adults

Enzyme Replacement Drug OK'd for Form of Batten Disease

Enzyme Replacement Drug OK'd for Form of Batten ...

Brineura will be used to treat children with late infantile neuronal ceroid lipofuscinosis type 2 Batten

is free, fast, and customized just for you!

Already a member?

Sign In Now »